(CercleFinance.com) – Bristol Myers Squibb today announced updated results from a study demonstrating that repotrectinib – a tyrosine kinase (TKI) inhibitor – continues to show high and durable response rates in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Updated results will be presented in an oral presentation at the 2023 ASLC World Conference on Lung Cancer.
Based on the results of this trial, the U.S. Food and Drug Administration has agreed to consider the New Drug Application for repotrectinib in patients with locally advanced or metastatic ROS1-positive NSCLC in the setting of priority review.
“This targeted therapy has real potential to change the treatment landscape and become a new standard of care for patients with ROS1-positive NSCLC,” commented Byoung Chul Cho, from Yonsei University College of Medicine (South Korea).
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
